Two Sigma Advisers LP Has $19.54 Million Stake in AtriCure, Inc. (NASDAQ:ATRC)

Two Sigma Advisers LP lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 3.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 639,400 shares of the medical device company's stock after selling 24,700 shares during the period. Two Sigma Advisers LP owned about 1.31% of AtriCure worth $19,540,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ATRC. Johnson Financial Group Inc. increased its holdings in AtriCure by 1,184.1% during the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock worth $49,000 after purchasing an additional 1,492 shares in the last quarter. Heck Capital Advisors LLC bought a new position in AtriCure during the 4th quarter worth about $60,000. Venturi Wealth Management LLC increased its holdings in AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after purchasing an additional 2,100 shares in the last quarter. KBC Group NV increased its holdings in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after purchasing an additional 932 shares in the last quarter. Finally, State of Wyoming increased its holdings in AtriCure by 21.9% during the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after purchasing an additional 446 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Insider Activity at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ATRC has been the subject of a number of research reports. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Canaccord Genuity Group lowered their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a report on Friday, March 28th. JPMorgan Chase & Co. decreased their price objective on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, March 27th. UBS Group decreased their price objective on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Finally, Wall Street Zen upgraded AtriCure from a "hold" rating to a "buy" rating in a report on Saturday. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $50.67.

AtriCure Stock Down 0.3%

Shares of NASDAQ ATRC traded down $0.10 during mid-day trading on Friday, hitting $32.71. The company had a trading volume of 330,069 shares, compared to its average volume of 650,988. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The company has a market capitalization of $1.62 billion, a PE ratio of -34.43 and a beta of 1.57. The firm has a 50-day simple moving average of $32.38 and a two-hundred day simple moving average of $34.80. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The business had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. During the same period last year, the business posted ($0.28) EPS. AtriCure's revenue was up 13.5% on a year-over-year basis. On average, equities analysts expect that AtriCure, Inc. will post -0.6 EPS for the current year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.